Navigation Links
Syndax Promotes John S. Pallies to Chief Financial Officer and Dr. Peter Ordentlich to Chief Technology Officer
Date:11/1/2013

WALTHAM, Mass., Nov. 1, 2013 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. today announced the promotion of John S. Pallies to chief financial officer from vice president, finance and administration, and co-founder Peter Ordentlich, Ph.D., to chief technology officer from vice president, translational medicine. Both appointments are effective Nov.1, 2013.

"These promotions are recognition of the exceptional work John and Peter have done helping Syndax develop to the point of being ready to begin a Phase 3 trial of entinostat in patients with advanced breast cancer," said Arlene M. Morris, Syndax's chief executive officer. "John has been leading the financial operations of Syndax for more than six years and Peter co-founded the company based on scientific discoveries at the Salk Institute for Biological Studies. We are confident John's financial insight and strategic aptitude and Peter's unique clinical and scientific expertise will help Syndax continue successful development of entinostat for the treatment of breast cancer and other malignancies."

Mr. Pallies joined Syndax in 2007 with more than a decade of experience in biotech, high-tech start-ups and management consulting focused on developing corporate and financial infrastructures and managing multiple business operations. Prior to co-founding Syndax in 2005, Dr. Ordentlich was a scientist at the Salk Institute for Biological Studies in La Jolla, California, working with Dr. Ronald M. Evans to identify small molecules as potential therapeutics and evaluating synergistic combinations of histone deacetylase inhibitors and nuclear receptor ligands.

About Syndax Pharmaceuticals

Syndax is late stage biopharmaceutical company focused on the development and commercialization of its lead product candidate, entinostat, an epigenetic therapy for treatment-resistant cancers. Entinostat was recently granted Breakthrough Therapy designation by the U.S. Food and Drug Administration.

Corporate Contact:
Bob Goodenow
Chief Business Officer
Syndax Pharmaceuticals
(781) 419-1418
BGoodenow@Syndax.com

Media Contacts:
David Schull or Matt Middleman, M.D.
Russo Partners
(212) 845-4271
(212) 845-4272
david.schull@russopartnersllc.com  
matt.middleman@russopartnersllc.com


'/>"/>
SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Syndaxs Entinostat Receives Breakthrough Therapy Designation from FDA for Treatment of Advanced Breast Cancer
2. Syndax and Eddingpharm Enter into a License Agreement Giving Eddingpharm Rights to Commercialize Entinostat in China and Other Asian Countries
3. Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers
4. Syndax Pharmaceuticals Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer
5. Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO
6. Medela Promotes Human Milk Consumption in NICUs to Address Health Risks Associated with Prematurity and Improve Infant Health
7. SynteractHCR Promotes Education to Take Time and Cost out of Drug Development with ICD+ Webinar Series
8. Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer
9. Lower Extremity Functional Electrical Stimulation Cycling Promotes Physical & Neurological Recovery in Chronic Spinal Cord Injury
10. OncoSec Medical Promotes Veronica Vallejo to Chief Financial Officer
11. Biomarkers in Drug Discovery - Integration in Early Stage Promotes Use of Companion Diagnostics to Optimize Therapeutic Outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... Oct. 10, 2017  NDS received FDA 510(k) clearance in May ... battery-powered display stand specifically designed for endoscopy environments. An innovative secondary ... a clinical solution to support the improvement of patient outcomes, procedural ... ... ...
(Date:10/4/2017)... -- According to the Centers for Disease Control and Prevention (CDC), influenza ... Care is helping communities across Massachusetts , ... no-cost* flu shots through the end of the month. *Some ... ... flu shot is by the end of October, according to the Centers ...
(Date:10/2/2017)... Labs announces the European launch of their new low volume, high ... in Cambridge, U.K on October 4th. The ... with unprecedented speed and sensitivity while using far less sample volume ... ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... certification process to promote standards of excellence for the field of eating disorders, ... March 22 – 25, 2018 in Orlando, Florida at the Omni Resort at ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, ... lowdown on sciatica in a new episode of "Success Files," which is an ... and innovation and investigates each subject in-depth with passion and integrity. , Sciatica ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
Breaking Medicine News(10 mins):